OpenLB
Open Library of Bioscience
Advanced Search
Frontiers in molecular biosciences
2022;9 889403.

Development of Molecular Mechanisms and Their Application on Oncolytic Newcastle Disease Virus in Cancer Therapy.

Fang Huang, Chuanjing Dai, Youni Zhang, Yuqi Zhao, Yigang Wang, Guoqing Ru
Author Information
  1. Fang Huang: Cancer Center, Department of Pathology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, China.
  2. Chuanjing Dai: Cancer Center, Department of Pathology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, China.
  3. Youni Zhang: College of Life Sciences and Medicine, Xinyuan Institute of Medicine and Biotechnology, Zhejiang Sci-Tech University, Hangzhou, China.
  4. Yuqi Zhao: College of Life Sciences and Medicine, Xinyuan Institute of Medicine and Biotechnology, Zhejiang Sci-Tech University, Hangzhou, China.
  5. Yigang Wang: College of Life Sciences and Medicine, Xinyuan Institute of Medicine and Biotechnology, Zhejiang Sci-Tech University, Hangzhou, China.
  6. Guoqing Ru: Cancer Center, Department of Pathology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, China.
PMID: 35860357 DOI: 10.3389/fmolb.2022.889403

Abstract

Cancer is caused by the destruction or mutation of cellular genetic materials induced by environmental or genetic factors. It is defined by uncontrolled cell proliferation and abnormality of the apoptotic pathways. The majority of human malignancies are characterized by distant metastasis and dissemination. Currently, the most common means of cancer treatment include surgery, radiotherapy, and chemotherapy, which usually damage healthy cells and cause toxicity in patients. Targeted therapy is an effective tumor treatment method with few side effects. At present, some targeted therapeutic drugs have achieved encouraging results in clinical studies, but finding an effective solution to improve the targeting and delivery efficiency of these drugs remains a challenge. In recent years, oncolytic viruses (OVs) have been used to direct the tumor-targeted therapy or immunotherapy. Newcastle disease virus (NDV) is a solid oncolytic agent capable of directly killing tumor cells and increasing tumor antigen exposure. Simultaneously, NDV can trigger the proliferation of tumor-specific immune cells and thus improve the therapeutic efficacy of NDV in cancer. Based on NDV's inherent oncolytic activity and the stimulation of antitumor immune responses, the combination of NDV and other tumor therapy approaches can improve the antitumor efficacy while reducing drug toxicity, indicating a broad application potential. We discussed the biological properties of NDV, the antitumor molecular mechanisms of oncolytic NDV, and its application in the field of tumor therapy in this review. Furthermore, we presented new insights into the challenges that NDV will confront and suggestions for increasing NDV's therapeutic efficacy in cancer.

Keywords

Newcastle disease virus antitumor immunity apoptosis oncolytic virotherapy tumor

References

Cancer. 1983 Sep 1;52(5):856-60 [PMID: 6871827]
Mol Ther. 2010 Feb;18(2):275-84 [PMID: 19809404]
Arch Virol. 2017 Jul;162(7):1845-1854 [PMID: 28316014]
J Gastrointest Surg. 2010 Jan;14(1):7-14 [PMID: 19902312]
J Clin Oncol. 2002 May 1;20(9):2251-66 [PMID: 11980996]
Saudi J Biol Sci. 2020 Jan;27(1):47-52 [PMID: 31889816]
Nat Rev Drug Discov. 2019 Sep;18(9):689-706 [PMID: 31292532]
Int J Oncol. 2004 Mar;24(3):623-34 [PMID: 14767547]
Eur J Pharmacol. 2017 May 5;802:85-92 [PMID: 28246027]
Gene Ther. 2003 Feb;10(4):292-303 [PMID: 12595888]
Front Oncol. 2017 Aug 24;7:179 [PMID: 28884088]
Am J Cancer Res. 2018 Aug 01;8(8):1514-1527 [PMID: 30210920]
Mol Ther Oncolytics. 2021 Jan 21;20:306-324 [PMID: 33614913]
Int J Mol Sci. 2018 Jun 15;19(6): [PMID: 29914057]
Oncol Lett. 2021 Jun;21(6):482 [PMID: 33968198]
Sci Rep. 2019 Aug 28;9(1):12492 [PMID: 31462656]
Front Oncol. 2014 Sep 11;4:224 [PMID: 25309868]
Methods Mol Biol. 2012;797:177-204 [PMID: 21948477]
Acta Naturae. 2019 Jan-Mar;11(1):66-73 [PMID: 31024750]
Oncoimmunology. 2013 Apr 1;2(4):e23658 [PMID: 23734319]
Future Microbiol. 2012 Mar;7(3):347-67 [PMID: 22393889]
Arch Virol. 2012 Apr;157(4):765-8 [PMID: 22218968]
Mol Ther. 2006 Jan;13(1):221-8 [PMID: 16257582]
Anat Rec (Hoboken). 2013 Oct;296(10):1552-60 [PMID: 23959779]
Hum Gene Ther. 2019 Jan;30(1):3-9 [PMID: 30045635]
J Cell Biochem. 2021 Jan;122(1):3-15 [PMID: 32985706]
Thorac Cancer. 2018 Nov;9(11):1437-1452 [PMID: 30246439]
Cancer Res. 2004 Nov 1;64(21):8057-61 [PMID: 15520216]
Eur Radiol. 2020 Jan;30(1):558-570 [PMID: 31444598]
Am J Cancer Res. 2016 May 01;6(5):924-36 [PMID: 27293989]
Cancer. 1965 Jul;18:863-8 [PMID: 14308233]
Anticancer Res. 1999 Jan-Feb;19(1B):635-8 [PMID: 10216468]
Eur Rev Med Pharmacol Sci. 2019 Oct;23(20):8771-8778 [PMID: 31696463]
Int J Oncol. 2009 Apr;34(4):971-82 [PMID: 19287954]
Biomed Res Int. 2014;2014:386470 [PMID: 25243137]
Int Immunopharmacol. 2021 Oct;99:107929 [PMID: 34343940]
Cancers (Basel). 2020 Nov 28;12(12): [PMID: 33260685]
Drug Discov Today. 2020 Jul;25(7):1198-1205 [PMID: 32344041]
Int J Med Sci. 2021 Mar 30;18(11):2294-2302 [PMID: 33967605]
J Cell Mol Med. 2020 Apr;24(7):4286-4297 [PMID: 32100392]
Oncoimmunology. 2015 Dec 8;5(2):e1117740 [PMID: 27057469]
Cells. 2020 Oct 16;9(10): [PMID: 33081387]
Autophagy. 2018;14(10):1665-1673 [PMID: 29895192]
J Immunol Res. 2015;2015:308574 [PMID: 26579545]
Autophagy. 2022 Jul;18(7):1503-1521 [PMID: 34720029]
Transbound Emerg Dis. 2017 Feb;64(1):53-67 [PMID: 25924108]
Cell Death Dis. 2019 Nov 26;10(12):891 [PMID: 31767828]
Onco Targets Ther. 2020 May 11;13:3987-3998 [PMID: 32523351]
Am J Cancer Res. 2015 Nov 15;5(12):3612-23 [PMID: 26885450]
Nat Biotechnol. 2018 Apr;36(4):346-351 [PMID: 29505028]
Virus Res. 2015 Nov 2;209:56-66 [PMID: 26221764]
Virology. 2014 Aug;462-463:283-94 [PMID: 24999841]
Avian Pathol. 2001 Oct;30(5):439-55 [PMID: 19184932]
Arch Virol. 2017 Sep;162(9):2705-2713 [PMID: 28578522]
Viruses. 2020 Apr 16;12(4): [PMID: 32316317]
BMC Cancer. 2019 Apr 4;19(1):315 [PMID: 30947706]
Cancer Immunol Immunother. 1989;28(1):22-8 [PMID: 2462467]
Biochem Biophys Res Commun. 2011 Mar 25;406(4):552-7 [PMID: 21352803]
Life Sci. 2021 Mar 15;269:119087 [PMID: 33476633]
Oncotarget. 2017 Jun 27;8(26):43201-43217 [PMID: 28591723]
Sci Rep. 2019 Sep 30;9(1):13999 [PMID: 31570732]
PLoS One. 2016 Feb 09;11(2):e0148560 [PMID: 26859759]
CA Cancer J Clin. 2021 May;71(3):209-249 [PMID: 33538338]
PET Clin. 2018 Jul;13(3):339-354 [PMID: 30100074]
J Mol Med (Berl). 2010 Jun;88(6):589-96 [PMID: 20393691]
Oncol Lett. 2018 Jul;16(1):1180-1188 [PMID: 30061941]
PLoS Pathog. 2020 Jun 30;16(6):e1008610 [PMID: 32603377]
Int J Cancer. 2015 Mar 1;136(5):E313-25 [PMID: 25208916]
PeerJ. 2020 Dec 8;8:e9761 [PMID: 33354412]
Cell Cycle. 2019 Oct;18(20):2757-2769 [PMID: 31438772]
J Exp Med. 2011 Sep 26;208(10):2005-16 [PMID: 21930765]
Int J Mol Med. 2013 Mar;31(3):525-32 [PMID: 23337979]
Annu Rev Pharmacol Toxicol. 2001;41:367-401 [PMID: 11264462]
J Gen Virol. 1999 Nov;80 ( Pt 11):2987-2995 [PMID: 10580061]
World J Gastroenterol. 2003 Mar;9(3):495-8 [PMID: 12632504]
World J Clin Cases. 2019 Aug 26;7(16):2143-2154 [PMID: 31531310]
Virus Res. 2021 Jan 15;292:198223 [PMID: 33166563]
J Virol. 2010 Apr;84(8):3835-44 [PMID: 20147405]
J Virol. 1999 Jun;73(6):5001-9 [PMID: 10233962]
Biochim Biophys Acta. 2014 Jan;1838(1 Pt B):300-9 [PMID: 23994097]
Infect Genet Evol. 2016 Apr;39:22-34 [PMID: 26792710]
Vaccines (Basel). 2020 May 14;8(2): [PMID: 32422944]
Cancer Gene Ther. 2008 Dec;15(12):795-807 [PMID: 18535620]
Med Sci Monit. 2019 Jul 24;25:5482-5492 [PMID: 31337746]
J Clin Oncol. 2004 Nov 1;22(21):4272-81 [PMID: 15452186]
Mol Ther Oncolytics. 2019 Mar 27;13:22-34 [PMID: 31011625]
Mol Med. 1998 Dec;4(12):783-94 [PMID: 9990864]
Nat Commun. 2021 Aug 11;12(1):4853 [PMID: 34381046]
Mol Cancer. 2015 Feb 21;14:48 [PMID: 25743109]
J Biomed Biotechnol. 2011;2011:718710 [PMID: 22131816]
Autophagy. 2017 Mar 4;13(3):452-463 [PMID: 28055310]
Mol Cell. 2020 Jun 18;78(6):1002-1018 [PMID: 32559422]
Oncotarget. 2017 May 23;8(21):34516-34524 [PMID: 28388537]
J Virol. 2013 Apr;87(7):3792-800 [PMID: 23345509]
Curr Probl Cancer. 2021 Feb;45(1):100639 [PMID: 32828575]
Sci Transl Med. 2014 Mar 5;6(226):226ra32 [PMID: 24598590]
Medicine (Baltimore). 2015 Sep;94(39):e1631 [PMID: 26426650]
Adv Exp Med Biol. 2021;1290:67-80 [PMID: 33559855]
J Immunother Cancer. 2018 Dec 4;6(1):140 [PMID: 30514385]
Saudi J Biol Sci. 2021 Oct;28(10):5833-5840 [PMID: 34588898]
Cancer. 1977 Aug;40(2):672-9 [PMID: 196739]
Redox Biol. 2021 Jul;43:101993 [PMID: 33946018]
Clin Ther. 2016 Jul;38(7):1551-66 [PMID: 27158009]
Arch Razi Inst. 2020 Oct;75(3):367-376 [PMID: 33025777]
Virus Res. 2014 May 12;184:71-81 [PMID: 24589707]
Viruses. 2021 Jul 21;13(8): [PMID: 34452286]
Br J Cancer. 2020 Jan;122(1):111-120 [PMID: 31819179]
Eur J Heart Fail. 2019 Oct;21(10):1259-1266 [PMID: 31359563]
Cancer. 1977 Aug;40(2):680-6 [PMID: 196740]
Prog Vet Microbiol Immunol. 1989;5:16-64 [PMID: 2696520]
PLoS One. 2012;7(12):e52751 [PMID: 23285174]
Brief Funct Genomics. 2019 Mar 22;18(2):107-112 [PMID: 30388190]
J Mol Endocrinol. 2020 Jan;64(1):1-12 [PMID: 31710594]
World J Stem Cells. 2022 Jan 26;14(1):41-53 [PMID: 35126827]
Vaccines (Basel). 2017 Sep 26;5(4): [PMID: 28954433]
Braz J Microbiol. 2016 Jan-Mar;47(1):231-42 [PMID: 26887250]
Cytometry A. 2018 Jan;93(1):32-49 [PMID: 28906582]
Nat Rev Clin Oncol. 2018 Feb;15(2):81-94 [PMID: 29115304]
Sci Rep. 2018 Jul 31;8(1):11470 [PMID: 30065314]
PLoS One. 2017 Sep 21;12(9):e0184347 [PMID: 28934210]
BMC Cancer. 2019 Oct 22;19(1):976 [PMID: 31640627]
Int J Cancer. 2006 Jul 15;119(2):328-38 [PMID: 16470838]
Adv Drug Deliv Rev. 2016 Mar 1;98:35-40 [PMID: 26724249]
iScience. 2021 Jul 10;24(8):102837 [PMID: 34368653]
Nat Med. 2000 Jul;6(7):821-5 [PMID: 10888934]
Oncol Rep. 2016 Sep;36(3):1393-402 [PMID: 27430534]
Virus Res. 2010 Jan;147(1):153-7 [PMID: 19896994]
Front Mol Biosci. 2019 Sep 27;6:90 [PMID: 31612140]
Hepatol Int. 2020 May;14(3):373-384 [PMID: 31440992]
Autophagy. 2016 Oct 2;12(10):1738-1758 [PMID: 27463126]
J Immunother Cancer. 2019 Jun 6;7(1):145 [PMID: 31171039]
J Pathol. 2019 Apr;247(5):708-718 [PMID: 30570140]
J Pharmacol Sci. 2016 Sep;132(1):24-30 [PMID: 27174862]
Chin Med J (Engl). 2022 Feb 9;135(5):584-590 [PMID: 35143424]
Sci Rep. 2016 Apr 21;6:24721 [PMID: 27097866]
Stem Cell Res Ther. 2016 Oct 10;7(1):149 [PMID: 27724977]
Cancer Immunol Immunother. 2020 Jun;69(6):1015-1027 [PMID: 32088771]
JAMA Oncol. 2017 Jun 01;3(6):841-849 [PMID: 27441411]
Cancer Immunol Res. 2015 Sep;3(9):1052-62 [PMID: 25943534]
Oncol Lett. 2016 Nov;12(5):3344-3350 [PMID: 27900002]
Signal Transduct Target Ther. 2020 Mar 12;5(1):28 [PMID: 32296047]
J Clin Virol. 2000 Feb;16(1):1-15 [PMID: 10680736]
Viruses. 2021 Jun 11;13(6): [PMID: 34208264]
Virus Res. 2000 Jan;66(1):1-11 [PMID: 10653913]
J Exp Clin Cancer Res. 2015 Dec 21;34:153 [PMID: 26689432]
Hum Vaccin Immunother. 2020 Oct 2;16(10):2389-2402 [PMID: 32078405]
World J Gastroenterol. 2017 Sep 14;23(34):6330-6338 [PMID: 28974900]
Cancers (Basel). 2020 Apr 21;12(4): [PMID: 32326341]
Oncotarget. 2014 Aug 15;5(15):6365-74 [PMID: 25051374]
Sci Rep. 2016 May 05;6:25447 [PMID: 27146881]
Autophagy. 2017 Jul 3;13(7):1093-1112 [PMID: 28513279]
Mol Ther. 2018 Jun 6;26(6):1414-1422 [PMID: 29703699]
Oncol Lett. 2014 Dec;8(6):2569-2576 [PMID: 25364430]
Technol Cancer Res Treat. 2014 Apr;13(2):169-75 [PMID: 23819497]
J Interferon Cytokine Res. 2013 Jul;33(7):346-54 [PMID: 23506478]
Oncol Res. 2011;19(7):323-33 [PMID: 21936402]
Vet Pathol. 2018 Sep;55(5):682-692 [PMID: 29661124]
Cancer Gene Ther. 2014 Jan;21(1):24-30 [PMID: 24384773]
J Hepatol. 2021 Feb;74(2):458-465 [PMID: 33303216]
Int J Oncol. 2015 Jan;46(1):71-7 [PMID: 25354198]
Cancer Biol Ther. 2014 Sep;15(9):1226-38 [PMID: 24971746]
Cold Spring Harb Perspect Biol. 2009 Dec;1(6):a001651 [PMID: 20457564]
Med Oncol Tumor Pharmacother. 1992;9(4):169-71 [PMID: 1342060]
PLoS One. 2014 Jun 04;9(6):e98869 [PMID: 24897503]
Sci Rep. 2019 Oct 22;9(1):15160 [PMID: 31641164]
Cell Oncol (Dordr). 2015 Aug;38(4):279-88 [PMID: 25930675]
Mol Ther. 2018 Apr 4;26(4):1008-1019 [PMID: 29478729]
Asian Pac J Cancer Prev. 2019 Oct 01;20(10):3071-3075 [PMID: 31653156]
N Engl J Med. 1964 Sep 24;271:645-51 [PMID: 14170843]
Vet Microbiol. 2021 Sep;260:109167 [PMID: 34274763]
Virol J. 2020 May 5;17(1):64 [PMID: 32370750]
J Virol. 2011 Jun;85(12):6015-23 [PMID: 21471241]
Mol Med Rep. 2015 Jan;11(1):317-26 [PMID: 25322856]
Virus Res. 2008 Sep;136(1-2):75-80 [PMID: 18538434]
Virusdisease. 2020 Sep;31(3):341-348 [PMID: 32904847]
Cytokine Growth Factor Rev. 2020 Dec;56:39-48 [PMID: 32718830]
Methods Mol Biol. 2009;542:565-605 [PMID: 19565923]
Cancer Cell Int. 2020 Aug 28;20:420 [PMID: 32874134]
Oncolytic Virother. 2017 Mar 03;6:21-30 [PMID: 28293547]
J Biomed Sci. 2016 Jul 28;23(1):55 [PMID: 27465066]
Sci Transl Med. 2020 Jan 15;12(526): [PMID: 31941828]
Front Oncol. 2019 May 29;9:436 [PMID: 31192135]
World J Gastroenterol. 2018 Nov 7;24(41):4643-4651 [PMID: 30416312]
Infect Agent Cancer. 2019 Feb 11;14:5 [PMID: 30792754]
Nature. 2013 Sep 19;501(7467):328-37 [PMID: 24048065]
Dev Comp Immunol. 2013 Nov;41(3):447-53 [PMID: 23623955]
J Neurooncol. 2004 Mar-Apr;67(1-2):83-93 [PMID: 15072452]
Vet Immunol Immunopathol. 2017 Dec;193-194:18-28 [PMID: 29129224]
Journal Article Review

Word Cloud

Similar Articles

Cited By